AML: could pretransplant nutritional interventions improve OS?

  • Ando T & al.
  • Int J Hematol
  • 8 Apr 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with acute myeloid leukemia (AML) who received standard chemotherapy, reduced weight at the time of hematopoietic stem cell transplantation (HSCT) was associated with inferior survival outcomes.

Why this matters

  • This is one of the largest studies regarding changes in weight and post-HSCT outcomes in this setting.

Study design

  • Study to investigate associations between BMI change after intensive chemotherapy and post-HSCT survival outcomes in 184 patients with newly diagnosed AML.
  • When stratified by BMI at transplant minus BMI at diagnosis (d-BMI):
    • 13.1% were d-BMI 2.
    • 70.6% were d-BMI −2 to +2 kg/m2.
    • 16.3% were d-BMI >+2 kg/m2.
  • Funding: Yokohama Cooperative Study Group for Hematology.

Key results

  • Graft-vs-host DFS (GRFS) by d-BMI category (P=.0067):
    • 16.1% (95% CI, 5.1%-31.4%) in patients with d-BMI 2.
    • 45.4% (95% CI, 36.4%-53.7%) in patients with d-BMI −2 to +2 kg/m2.
    • 41.7% (95% CI, 22.2%-60.1%) in patients with d-BMI >+2 kg/m2.
  • In multivariate analysis:
    • Significant correlation between d-BMI 2 and inferior OS vs weight maintenance group: HR, 1.78; 95% CI, 1.02-3.14; P=.045.
    • Significant association between d-BMI 2 and inferior GRFS: HR, 2.34; 95% CI, 1.16-4.35; P=.007.

Limitations

  • Limited sample size.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit